Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by <em>Enterobacteriaceae</em>

• Main Authors: Ga Eun Park (Author), Jae-Hoon Ko (Author), Sun Young Cho (Author), Hee Jae Huh (Author), Jin Yang Baek (Author), Kwan Soo Ko (Author), Cheol-In Kang (Author), Doo Ryeon Chung (Author), Kyong Ran Peck (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for <i>Enterobacteriaceae</i> from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP brea...